JP2018522887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522887A5 JP2018522887A5 JP2018501155A JP2018501155A JP2018522887A5 JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5 JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hpv
- subject
- antibody according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701806 Human papillomavirus Species 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012303 cytoplasmic staining Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000012758 nuclear staining Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169277A JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192396P | 2015-07-14 | 2015-07-14 | |
| US62/192,396 | 2015-07-14 | ||
| PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Division JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522887A JP2018522887A (ja) | 2018-08-16 |
| JP2018522887A5 true JP2018522887A5 (cg-RX-API-DMAC7.html) | 2019-08-22 |
Family
ID=56551000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501155A Withdrawn JP2018522887A (ja) | 2015-07-14 | 2016-07-14 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544224B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3858859B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2018522887A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20180027576A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107922502A (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123993T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3322731T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2855798T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3858859T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20210399T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE053966T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3322731T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3322731T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3322731T (cg-RX-API-DMAC7.html) |
| RS (1) | RS61532B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3322731T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202100131T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017011666A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| RS60792B1 (sr) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antitela i postupci za njihovu primenu |
| WO2017004079A1 (en) | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| HUE053966T2 (hu) | 2015-07-14 | 2021-08-30 | Bristol Myers Squibb Co | Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| LT3377534T (lt) * | 2015-11-18 | 2025-08-11 | Bristol-Myers Squibb Company | Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį |
| RU2018125603A (ru) * | 2015-12-17 | 2020-01-21 | Новартис Аг | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения |
| WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
| EP3484478B1 (en) * | 2016-07-15 | 2025-11-05 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| US11274154B2 (en) * | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
| MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| WO2018226529A1 (en) * | 2017-06-05 | 2018-12-13 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| TW201932839A (zh) * | 2018-01-12 | 2019-08-16 | 美商格瑞爾公司 | 用於分析病毒核酸之方法 |
| MA51844A (fr) * | 2018-02-13 | 2021-05-19 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3801501A4 (en) | 2018-06-06 | 2022-03-23 | The Regents of the University of California | ESTROGEN RECEPTOR INHIBITORS AND THEIR USES |
| US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
| CN114340679A (zh) * | 2018-10-31 | 2022-04-12 | 基因泰克公司 | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| CA3162311A1 (en) * | 2019-12-20 | 2021-06-24 | Philip E. Brandish | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
| KR102779377B1 (ko) | 2022-07-22 | 2025-03-12 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE293640T1 (de) | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| AU3475100A (en) | 1999-01-29 | 2000-08-18 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| ATE510561T1 (de) | 2002-03-04 | 2011-06-15 | Imclone Llc | Kdr-spezifische menschliche antikörper und ihre verwendung |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| US7972596B2 (en) | 2004-11-18 | 2011-07-05 | Imclone Llc | Antibodies against vascular endothelial growth factor receptor-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| NZ601439A (en) * | 2005-06-08 | 2012-11-30 | Brigham & Womens Hospital | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ，インコーポレーテッド | 抗ｖｅｇｆ抗体の組成物および方法 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CA2887027C (en) | 2012-10-02 | 2021-11-16 | Bristol-Myers Squibb Company | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| SG11201609468WA (en) * | 2014-05-29 | 2016-12-29 | Medimmune Ltd | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| ES2813580T3 (es) * | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Composiciones que comprenden una combinación de ipilimumab y nivolumab |
| HUE053966T2 (hu) | 2015-07-14 | 2021-08-30 | Bristol Myers Squibb Co | Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) |
-
2016
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 SM SM20210131T patent/SMT202100131T1/it unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en not_active Ceased
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja not_active Withdrawn
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Ceased
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 KR KR1020257014642A patent/KR20250065936A/ko active Pending
- 2016-07-14 EP EP20214749.2A patent/EP3858859B1/en active Active
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 DK DK20214749.2T patent/DK3858859T3/da active
- 2016-07-14 FI FIEP20214749.2T patent/FI3858859T3/fi active
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en active Active
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106098A patent/JP2025138726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522887A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018515474A5 (cg-RX-API-DMAC7.html) | ||
| JP2018514550A5 (cg-RX-API-DMAC7.html) | ||
| IL278423B1 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| JP2018500332A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528195A5 (cg-RX-API-DMAC7.html) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| JP2019503387A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525117A5 (cg-RX-API-DMAC7.html) | ||
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| JP2017534633A5 (cg-RX-API-DMAC7.html) | ||
| RU2017117664A (ru) | Комбинация | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2017537090A5 (cg-RX-API-DMAC7.html) | ||
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019517504A5 (cg-RX-API-DMAC7.html) | ||
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy | |
| ZA202201247B (en) | Bispecific antibody |